Core Viewpoint - Inovio Pharmaceuticals is actively pursuing accelerated approval for its treatment INO-3107, which addresses an unmet medical need for recurrent respiratory papillomatosis (RRP) and is under FDA review with a target date of October 30, 2026 [3][7]. Regulatory and Approval Process - The FDA has accepted Inovio's Biologics License Application (BLA) for INO-3107 under the Accelerated Approval Program, with a standard review timeline of 10 months [3]. - A preliminary concern was raised by the FDA regarding the adequacy of information provided to justify eligibility for accelerated approval [2][7]. - Inovio submitted an "assessment aid" to the FDA to expand its rationale and is awaiting a meeting to discuss eligibility [1][7]. Financial Performance and Cost Management - Inovio ended Q4 2025 with $58.5 million in cash, down from $94.1 million at the end of 2024, and projects a cash burn of approximately $22 million in Q1 2026 [5][22]. - The company has implemented cost-cutting measures, including a 15% reduction in headcount, to extend its cash runway into Q4 2026 [5][21]. - Total operating expenses decreased by 23% in 2025 compared to 2024, amounting to $86.9 million [22]. Clinical Differentiation and Market Positioning - Inovio claims that INO-3107 demonstrates significant differentiation from the recently approved PAPZIMEOS, with a majority of patients experiencing a 50%-100% reduction in surgeries [6][10]. - The treatment's efficacy was achieved without the majority of patients requiring surgery during the dosing window, which is considered a key advantage [10]. - Market research indicates that INO-3107 could become a preferred treatment option due to its efficacy and tolerability, as well as its administration in a physician's office without ultra-cold chain requirements [12][13]. Commercial Launch Preparations - Inovio is actively preparing for the commercial launch of INO-3107, having completed targeting, segmentation, and pricing strategy development [15]. - The RRP Foundation's position statement supports immunotherapy as a first-line treatment, which would include INO-3107 if approved [14]. - The company has selected key commercial partners and is finalizing its go-to-market model [15]. Pipeline and Future Developments - Beyond INO-3107, Inovio is pursuing partnerships to advance other programs, including a collaboration for a phase II trial involving INO-5412 [16][20]. - The company is also making progress in its DNA-encoded monoclonal antibodies (dMAbs) and DPROT programs, with promising preclinical data [18][19].

Financial Data and Key Metrics Changes - INOVIO reported a net income of $3.8 million for Q4 2025, translating to $0.06 per share, while the total net loss for the full year was $84.9 million or $1.81 per share [25][26] - Total operating expenses decreased from $20.5 million in Q4 2024 to $17.5 million in Q4 2025, and full-year operational expenses dropped 23% from $112.6 million in 2024 to $86.9 million in 2025 [25][26] - Cash equivalents and short-term investments at the end of Q4 2025 were $58.5 million, down from $94.1 million as of December 31, 2024 [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - INOVIO is also advancing other promising candidates in its pipeline, including INO-5412 for glioblastoma, through partnerships [8][22] Market Data and Key Metrics Changes - The market for recurrent respiratory papillomatosis (RRP) treatment is characterized by a significant burden on patients, with surgery being the standard of care [15] - Market research indicates that INO-3107 has the potential to become the preferred treatment option based on its efficacy and tolerability [16][18] Company Strategy and Development Direction - INOVIO's strategy includes optimizing resources to extend cash runway towards the October 30, 2026 PDUFA date for INO-3107 [24][60] - The company is leveraging partnerships to advance its pipeline and is focused on innovative treatments for rare diseases with significant unmet needs [22][60] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [5][11] - The company is preparing for a meeting with the FDA to discuss the Accelerated Approval Program and has submitted additional documentation to support its case [10][30] Other Important Information - INOVIO has reduced its workforce by approximately 15% to conserve financial resources [24] - The company is actively preparing for the commercial launch of INO-3107, including selecting key commercial partners and finalizing its go-to-market model [19][24] Q&A Session Summary Question: What additional data is needed for the FDA regarding Accelerated Approval? - Management indicated that no new clinical data is required, but they have submitted an Assessment Aid to reiterate their rationale for Accelerated Approval [29][30] Question: How would a six-month priority review timeline impact launch preparations? - Management stated that they are focused on ensuring alignment with the FDA for Accelerated Approval and are well advanced in commercial preparations [33][34] Question: How are third-party logistics and commercial partners being used to inform distribution strategy? - Management noted that they are learning from competitors and leveraging the experience of their partners to ensure a well-prepared launch [42][43] Question: Can you explain the rationale behind the Akeso partnership for GBM? - Management explained that combining PD-1 and CTLA-4 blockade is expected to enhance immune responses against tumor-associated antigens [48][49] Question: What are the plans for moving forward with 3112 if INO-3107 is approved? - Management indicated that resources are currently focused on INO-3107, but if approved, they will consider advancing 3112 based on available financial resources [55]

Financial Data and Key Metrics Changes - The company reported a net income of $3.8 million for Q4 2025, translating to $0.06 per share, while the full-year net loss was $84.9 million or $1.81 per share [25][26] - Total operating expenses decreased from $112.6 million in 2024 to $86.9 million in 2025, marking a 23% reduction [25] - Cash equivalents and short-term investments decreased from $94.1 million at the end of 2024 to $58.5 million at the end of Q4 2025 [25] Business Line Data and Key Metrics Changes - The primary focus remains on advancing INO-3107 towards FDA approval, with significant resources allocated to this lead candidate [5][24] - The company has also advanced its DNA medicine platform, including promising phase 1 proof of concept data for dMAb technology [21] Market Data and Key Metrics Changes - The market for recurrent respiratory papillomatosis (RRP) treatment is characterized by a significant burden on patients, with many requiring numerous surgeries throughout their lives [15] - Market research indicates that INO-3107 could become the preferred treatment option based on its efficacy and tolerability [16] Company Strategy and Development Direction - The company is focused on optimizing resources to extend its cash runway towards the October 30, 2026 PDUFA date for INO-3107 [24][60] - Strategic partnerships are being leveraged to advance other promising candidates in the pipeline, including collaborations in glioblastoma research [8][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in INO-3107's ability to meet an unmet medical need and provide a meaningful therapeutic benefit over existing treatments [7][11] - The company is preparing for a meeting with the FDA to discuss the BLA for INO-3107 and is awaiting feedback on an updated protocol for a confirmatory trial [10][30] Other Important Information - The company has reduced headcount by approximately 15% to conserve financial resources [24] - The FDA has accepted the BLA for INO-3107 under the Accelerated Approval Program, with a standard review timeline of 10 months [5][9] Q&A Session Summary Question: Additional data needed for FDA conversations regarding accelerated approval - Management confirmed that no new clinical data is required, but they have submitted new documentation to the FDA [30] Question: Impact of a potential priority review on launch preparations - The focus is currently on ensuring alignment with the FDA for accelerated approval, with commercial preparations well advanced [34][35] Question: Feedback from KOLs and patients on recent publications - Research indicates a strong preference for INO-3107 based on its efficacy and tolerability, with significant reductions in surgeries reported by patients [37][38] Question: Incorporating learnings from competitor's rollout into distribution strategy - The company is learning from competitor experiences and ensuring that their distribution strategy is well-prepared for launch [42][44] Question: Biological rationale of the dual PD-1/CTLA-4 blockade in partnership with Akeso - The combination aims to enhance immune responses against tumor-associated antigens, building on previous encouraging data [48][49] Question: Plans for INO-3112 if INO-3107 is approved - The company plans to focus resources on INO-3107 first, with potential to advance INO-3112 following approval and available financial resources [55]

Company Overview - Inovio is a clinical stage biotech company focused on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [3]. Product Development - The company has submitted a Biologics License Application (BLA) for its lead program, INO-3107, which targets recurrent respiratory papillomatosis (RRP) caused by HPV types 6 and 11 [4]. - The BLA has been accepted for review by the FDA under the accelerated approval program, with a PDUFA target date set for October 30 of this year [4]. - Inovio holds orphan drug and breakthrough therapy designations, as well as orphan drug designation in the EU for INO-3107 [4]. Regulatory Strategy - Inovio has requested a meeting with the FDA to discuss preliminary comments received regarding eligibility for the accelerated approval pathway and does not plan to seek approval under the traditional pathway [5].

Inovio Pharmaceuticals Conference Call Summary Company Overview - Inovio Pharmaceuticals is a clinical-stage biotech company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases [2][3] - The company has submitted a Biologics License Application (BLA) for its lead program, INO-3107, which targets Recurrent Respiratory Papillomatosis (RRP) caused by HPV types 6 and 11 [2][3] Regulatory Status - The BLA for INO-3107 has been accepted for review by the FDA under the Accelerated Approval Program, with a PDUFA target date of October 30, 2026 [3] - Inovio has received Orphan Drug and Breakthrough Therapy designations for INO-3107 [3] - The company is preparing to address preliminary comments from the FDA regarding eligibility for the Accelerated Approval Program [3][27] Product Details - INO-3107 is a combination product that includes a DNA medicine and a delivery device [3] - The treatment aims to generate an antigen-specific T-cell response against HPV6 and HPV11, addressing the underlying cause of RRP rather than just managing symptoms through surgery [9][10] - Epidemiology suggests approximately 14,000 active RRP cases in the U.S., with an incidence rate of 1.8 per 100,000 annually [7] Clinical Data - Efficacy data shows that 72% of patients experienced a 50%-100% reduction in surgeries in the first year, improving to 86% in the second year [11] - Complete response rates were 28% in year one and 50% in year two, indicating a significant reduction in the need for surgeries [11] - The treatment was well tolerated, with common adverse events being transient injection site pain (30% of participants) and fatigue, but no discontinuations were reported [12] Competitive Landscape - Inovio believes it has a preferred product profile compared to existing treatments, particularly due to its improved safety profile and the ability to administer the treatment in a doctor's office without the need for surgeries [29][45] - The approved product requires scoping and surgeries, which adds logistical burdens and risks for patients [45][63] Manufacturing and Commercialization - INO-3107 is manufactured at FDA-approved contract manufacturers, with the drug substance produced by one manufacturer and the final product filled by another [51] - The company is preparing for commercial launch, including market research and establishing distribution channels [58][61] Future Pipeline - Following INO-3107, Inovio has other candidates in development, including INO-5401 and INO-3112, which are T-cell based therapies [13][14] - The company is also exploring next-generation therapeutics for protein replacement diseases [14] Regulatory Feedback - Inovio has received differing feedback from European regulators, who are looking for placebo-controlled data and data from two efficacy trials, contrasting with the FDA's approach [39][41] Investor Insights - Inovio emphasizes the potential of its T-cell technology and the exciting prospects of its dMAb and dProt programs, which are gaining interest from potential partners [64][66]

Core Viewpoint - OS Therapies Inc. is advancing its Biologics License Application (BLA) for OST-HER2, a listeria-based cancer immunotherapy, aimed at preventing or delaying recurrent pulmonary metastatic osteosarcoma, with an expected submission of clinical data by the end of Q1 2026 [1][2]. Group 1: FDA Engagement and Designations - The FDA has elevated OS Therapies' Type D Biomarker Meeting to a Type B pre-BLA Meeting, indicating progress in discussions regarding Accelerated Approval for OST-HER2 [1]. - OST-HER2 has received multiple designations from the FDA, including Orphan Drug Designation (ODD), Fast Track Designation, and Rare Pediatric Disease Designation (RPDD) [2][3]. - If OST-HER2 receives Accelerated Approval, the company will be eligible for a Priority Review Voucher (PRV), which could be sold; the last reported PRV transaction was valued at $205 million [2]. Group 2: Clinical Trials and Efficacy - The company reported positive results from its Phase 2b clinical trial of OST-HER2, showing statistically significant benefits in the 12-month event-free survival (EFS) primary endpoint [3]. - A confirmatory randomized Phase 3 trial is planned to commence before the company can be granted Accelerated Approval in the U.S. [2]. Group 3: Future Developments - OS Therapies is also working on next-generation Antibody Drug Conjugates (ADC) and Drug Conjugates (DC), utilizing proprietary technology for tailored treatment options [4]. - The company anticipates reading out data from a Phase 1b study of OST-504 in castration-resistant prostate cancer in the first half of 2026 [3].

Inovio Pharmaceuticals FY Conference Summary Company Overview - **Company**: Inovio Pharmaceuticals (NasdaqCM: INO) - **Focus**: Developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases [4][5] - **Lead Candidate**: INO-3107, targeting recurrent respiratory papillomatosis (RRP) caused by HPV 6 and 11 [4][5] Regulatory Updates - **BLA Acceptance**: INO-3107's Biologics License Application (BLA) accepted for review by the FDA under the Accelerated Approval Program with a PDUFA target date of October 30, 2026 [5][19] - **Designations**: Received Orphan Drug designation and Breakthrough Therapy designation from the FDA and Orphan Drug designation in the EU [5] - **Regulatory Challenges**: Disappointment over not receiving priority review; FDA indicated inadequate information for Accelerated Approval eligibility [19][20] Market Opportunity - **RRP Prevalence**: Approximately 14,000 active cases in the U.S., with potential underestimation of market opportunity [12][39] - **Surgery Burden**: Patients may require hundreds of surgeries over a lifetime, leading to significant unmet needs [12][13] - **Competitor Pricing**: Competitor's treatment priced at approximately $115K per dose, indicating a lucrative market for RRP treatments [39] Product Profile and Efficacy - **Efficacy Data**: INO-3107 shows a 50%-100% reduction in surgeries after treatment, with 72% in year 1 improving to 86% in year 2; 28% of patients required no surgeries in year 1, increasing to 50% in year 2 [14][15] - **Safety Profile**: Well-tolerated with transient injection site reactions; no treatment discontinuations reported [15] - **Administration**: Office-based administration with no need for ultra-cold chain storage, making it easier for healthcare professionals [16] Clinical Pipeline - **Future Trials**: Plans to initiate Phase III trial for INO-3112 and Phase II trial for INO-5401 in glioblastoma; advancing DPROT platform candidates from preclinical to Phase I [17][41] - **dMAb Technology**: Exciting early-stage technology with potential to unlock further applications of DNA medicines [6][41] Immunogenicity and Redosing Strategy - **Comparison with Adenoviral Approaches**: INO-3107 avoids generating immune responses against viral vectors, allowing for multiple redosing without the risk of neutralizing antibodies [35][36][38] - **Redosing Plans**: Potential annual redosing strategy post-approval to maintain cytotoxic T-cell responses [38] Upcoming Milestones - **PDUFA Date**: Focus on the upcoming PDUFA date in October 2026; awaiting FDA meeting to discuss preliminary comments [17][43] - **Market Research**: Ongoing research to support launch strategy and address unmet needs in the RRP community [39][40] Conclusion - Inovio Pharmaceuticals is positioned to address significant unmet needs in the RRP market with its lead candidate INO-3107, supported by promising efficacy and safety data. The company is actively engaging with regulatory bodies to navigate the approval process while also advancing its broader clinical pipeline.